Last reviewed · How we verify
SSGJ-613
At a glance
| Generic name | SSGJ-613 |
|---|---|
| Sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. (PHASE2)
- A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout (PHASE3)
- The MAD Study of SSGJ-613 in Healthy Subjects (PHASE1)
- A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout (PHASE1, PHASE2)
- Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSGJ-613 CI brief — competitive landscape report
- SSGJ-613 updates RSS · CI watch RSS
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. portfolio CI